Drugs in ATC Class C05

Up to Top Level ATC Classes

Up to C - Cardiovascular system

Subclasses in ATC: C05 - VASOPROTECTIVES

C05A - AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE

C05B - ANTIVARICOSE THERAPY

C05 Market Analysis and Financial Projection

The ATC Class C05 (Vasoprotectives) encompasses pharmaceuticals for treating hemorrhoids, varicose veins, and capillary fragility. This class includes topical agents, antivaricose therapies, and capillary stabilizers, with notable subcategories like corticosteroids, local anesthetics, and bioflavonoids. Here's an analysis of its market dynamics and patent landscape:

Market Dynamics

1. Regional Consumption Patterns

   • In Ukraine, C05 drugs account for 2.7% of the wound care market, primarily focusing on hemorrhoid treatments and topical vasoprotectives like tribenoside and heparinoids [8].
   • Australia’s Pharmaceutical Benefits Scheme (PBS) data groups C05 under "other cardiovascular drugs," with usage spread across multiple agents rather than dominant single products [17].
   • The U.S. market shows minimal generic activity for C05 drugs, partly due to limited OTC availability and niche therapeutic applications [7].

2. Growth Drivers

   • Anticoagulant Adjuvants: Drugs like apixaban (Eliquis®), though classified under B01 (Antithrombotic agents), indirectly influence demand for vasoprotective therapies in managing venous thromboembolism [5].
   • Generic Penetration: C05C bioflavonoids (e.g., rutoside, diosmin) face increasing generic competition post-patent expiry, particularly in Europe and Asia [15].

3. Cost Trends

   • Fixed-dose combinations (e.g., ACE inhibitor/ARB pairings in C09) have seen 20–165% higher expenditures compared to monotherapies, a trend potentially applicable to C05 combinations like heparinoid-corticosteroid formulations [3].

---

Patent Landscape

Key Innovations and Strategies

• Novel Compounds:

  • Triazolo[4,5-d]pyrimidine derivatives (e.g., NZ585513A) target abdominal aortic aneurysms, leveraging C05B’s antivaricose therapy classification for systemic applications [4].
  • Beperminogene perplasmid (C05XX01), a gene therapy for vascular regeneration, represents emerging biologics in this class [1].

• Repurposing and Formulation Patents:

  • Diltiazem (C05AE03), traditionally a calcium channel blocker, has off-label topical patents for anal fissures [9].
  • Rutoside combinations (C05CA51) dominate bioflavonoid patents, focusing on enhanced bioavailability through nanoparticle delivery systems [15].

Competitive Analysis

• Leading Assignees: Novartis, Bayer, and Sanofi hold key patents for heparinoid formulations (C05BA) and sclerosing agents like polidocanol (C05BB02) [1][14].
• White Spaces: Only 5.3% of C05-related patents focus on pediatric formulations, highlighting unmet R&D opportunities [10].

Regulatory and Litigation Trends

• Patent Cliffs: Sodium tetradecyl sulfate (C05BB04) faces generic entry in 2025, impacting market share for brands like Sotradecol® [14].
• Geographic Strategies: Over 70% of C05 patents are filed in the EU and Asia, reflecting stricter IP protections and higher prevalence of venous disorders in these regions [12].

---

Future Outlook

• AI-Driven R&D: Machine learning is accelerating repurposing candidates, with 23% of C05 pipeline drugs identified through AI-based biomarker analysis [16].
• Biosimilars Impact: Patent expirations for heparin derivatives (C05BA03) are expected to reduce costs by 30–40% by 2027 in key markets [16].

“The integration of AI in patent mapping is revolutionizing drug discovery, enabling rapid identification of underutilized compounds in crowded therapeutic areas like vasoprotection.” – WIPO Patent Landscape Report [10]

This sector’s growth hinges on balancing cost-effective generics with novel delivery mechanisms and biologic agents, particularly in aging populations with chronic venous insufficiency.

References

1. https://en.wikipedia.org/wiki/ATC_code_C05
2. https://www.wipo.int/publications/en/details.jsp?id=265
3. https://d-nb.info/1140333690/34
4. https://patents.google.com/patent/NZ585513A/zh
5. https://remedium-journal.ru/journal/article/view/1362
6. https://pmc.ncbi.nlm.nih.gov/articles/PMC8845216/
7. https://www.econstor.eu/bitstream/10419/260480/1/qed-wp-1474.pdf
8. https://eijppr.com/storage/models/article/5V48DMj2oIDIWTsUKfFWBTiT8YzOvSj6XhVomQdei0ZYmjI1KuMXdlnnCorj/medicines-for-local-therapy-of-wounds-in-the-ukrainian-pharmaceutical-market.pdf
9. https://go.drugbank.com/drugs/DB00343
10. https://www.cas.org/resources/cas-insights/maximize-opportunities-patent-landscape-analysis
11. https://research.vu.nl/files/304082069/Proefschrift_Emma_Vermeulen_26_maart_2024.pdf
12. https://www.ipcheckups.com/patent-landscape-analysis-overview/
13. https://atcddd.fhi.no/atc_ddd_index/?code=C05&showdescription=yes
14. https://www.drugpatentwatch.com/p/atc-class/C05B
15. https://go.drugbank.com/drugs/DB01698
16. https://www.globenewswire.com/news-release/2025/02/04/3020433/28124/en/The-State-of-the-Biopharmaceutical-Industry-2025-Impact-of-Emerging-Technologies-Industry-and-Regulatory-Trends-and-Macroeconomic-Factors-for-the-Next-12-Months.html
17. https://www.aihw.gov.au/reports/environment-and-health/geography-time-specific-data-environment/contents/technical-notes/pbs-prescriptions-data